Evidence map›Paper›PMID 20194480›Full record

SynthesisThe American journal of psychiatry2010

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.

Jian-Ping Zhang, Todd Lencz, Anil K Malhotra

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The American journal of psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 10 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 10 syntheses or guidelines pooled it, 203 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response.International journal of molecular sciences · 2024
    Review
  18. Article
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jian-Ping ZhangDivision of Psychiatry Research, Department of Psychiatry, The Zucker Hillside Hospital, 75-59 263rd St., Glen Oaks, NY 11004, USA. jzhang1@nshs.edu
Todd Lencz
Anil K Malhotra
Zucker Hillside Hospital · US

Funding

Striatal D2/D3 Dopamine receptor availability in first episode schizophreniaP50MH080173 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI KANE, JOHN M · 2008 to 2012
$10.4M
Trials Operation UnitP30MH074543 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI KANE, JOHN M · 2005 to 2009
$8.1M
Genetic Variation and Functional Disability in SchizophreniaR01MH079800 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI MALHOTRA, ANIL K · 2007 to 2011
$1.9M
Identifying &Characterizing Prodromal SchizophreniaK01MH065580 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI LENCZ, TODD · 2003 to 2007
$675k
NIMH NIH HHS 1P30MH-074543NIMH NIH HHS 1P50MH-080173NIMH NIH HHS 1R01MH-79800-01NIMH NIH HHS K01 MH065580NIMH NIH HHS K01MH65580NIMH NIH HHS P30 MH074543NIMH NIH HHS P50 MH080173NIMH NIH HHS R01 MH079800
6 · The paper itself

Abstract

objectiveSeveral lines of evidence suggest that antipsychotic drug efficacy is mediated by dopamine type 2 (D(2)) receptor blockade. Therefore, it seems plausible that variation in the DRD(2) gene is associated with clinical response to antipsychotic drug treatment. The authors conducted the first meta-analysis to examine the relationship between DRD2 polymorphisms and antipsychotic drug response.

methodA MEDLINE search of articles available up to December 31, 2008, yielded 18 prospective studies examining DRD2 gene variation and antipsychotic response in schizophrenia patients; of which, 10 independent studies met criteria for inclusion. Clinical response to antipsychotic treatment was defined as a 50% reduction of either the Brief Psychiatric Rating Scale total score or Positive and Negative Syndrome Scale total score at approximately 8 weeks of follow-up evaluation. Odds ratio was the primary effect-size measure and computed for each polymorphism in each study. Sufficient data were available for two DRD2 polymorphisms: -141C Ins/Del and Taq1A.

resultsSix studies reported results for the -141C Ins/Del polymorphism (total sample size: N=687). The Del allele carrier was significantly associated with poorer antipsychotic drug response relative to the Ins/Ins genotype. Eight studies assessed the Taq1A polymorphism and antipsychotic response (total sample size: N=748). There was no significant difference in the response rate among A1 allele carriers relative to individuals with the A2/A2 genotype or A2 allele carriers relative to individuals with the A1/A1 genotype.

conclusionsThe DRD2 genetic variation is associated with clinical response to antipsychotic drug treatment. These data may provide proof-of-principle for pharmacogenetic studies in schizophrenia.

Indexed as

AllelesAntipsychotic AgentsGenotypeHumansPolymorphism, GeneticPolymorphism, Single NucleotidePsychiatric Status Rating ScalesReceptors, Dopamine D2SchizophreniaTreatment OutcomeAntipsychotic AgentsReceptors, Dopamine D2

Identifiers

PMID20194480
PMCPMC2896457
OpenAlexW2102659586

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.